Literature DB >> 19357749

Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda.

Joshua Baalwa1, Harriet Mayanja-Kizza, Moses R Kamya, Laurence John, Andrew Kambugu, Robert Colebunders.   

Abstract

OBJECTIVES: To determine the proportion of patients developing active tuberculosis (TB) versus that of patients who experience worsening of TB, after initiating highly active anti retroviral therapy (HAART).
METHODS: Charts of HAART naïve patients with or without clinically active TB who consecutively commenced HAART at Mulago Hospital Infectious Diseases Institute were reviewed. Patients were assessed for worsening of TB on treatment or development of new active TB (unmasking of TB) after initiating HAART.
RESULTS: Of 271 patients without active TB at baseline who initiated HAART, 16 (5.9%) developed active TB within 6 months (early unmasking) and 10 (2.7%) after 6 months (late unmasking). Seven of 10 late unmasking patients had a past history of treatment for a TB disease episode. Of 45 patients who commenced HAART with coexisting active TB, 13 (29%) experienced worsening of TB symptoms, signs and/or radiological features. Nine of these 45 commenced HAART during the intensive phase of TB treatment, of whom 2 (22%) experienced worsening of TB. Thirty six of 45 started HAART during the continuation phase of TB treatment of whom 11 (31%), experienced worsening of TB. The median time from initiation of HAART to worsening of TB in patients on concurrent active TB treatment was 5 weeks, and 18 weeks to unmasking of new active tuberculosis.
CONCLUSION: Unmasking of TB was commonest in the first 6 months of HAART and declined in the subsequent months with most in the late unmasking group being TB recurrences. Worsening of TB occurred even after HAART was delayed to the continuation phase of TB treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19357749      PMCID: PMC2583270     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  20 in total

Review 1.  Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.

Authors:  W J Burman; B E Jones
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

2.  Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis.

Authors:  Somnuek Sungkanuparph; Asda Vibhagool; Piroon Mootsikapun; Ploenchan Chetchotisakd; Somsit Tansuphaswaswadikul; Chureeratana Bowonwatanuwong
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

3.  Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy.

Authors:  J E Fishman; E Saraf-Lavi; M Narita; E S Hollender; R Ramsinghani; D Ashkin
Journal:  AJR Am J Roentgenol       Date:  2000-01       Impact factor: 3.959

4.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Authors:  Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

5.  Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.

Authors:  Guilherme Santoro-Lopes; Ana Maria Felix de Pinho; Lee H Harrison; Mauro Schechter
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

6.  Paradoxical worsening of tuberculosis in HIV-infected persons.

Authors:  K A Wendel; K S Alwood; R Gachuhi; R E Chaisson; W R Bishai; T R Sterling
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

Review 7.  Paradoxical tuberculous reactions in HIV-infected patients.

Authors:  D Orlovic; R A Smego
Journal:  Int J Tuberc Lung Dis       Date:  2001-04       Impact factor: 2.373

8.  Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy.

Authors:  S J Buckingham; L J Haddow; P J Shaw; R F Miller
Journal:  Clin Radiol       Date:  2004-06       Impact factor: 2.350

9.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.

Authors:  Motasim Badri; Douglas Wilson; Robin Wood
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

10.  Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART.

Authors:  Wan Beom Park; Pyoeng Gyun Choe; Jae Hyun Jo; Sung-Han Kim; Ji Hwan Bang; Hong Bin Kim; Nam Joong Kim; Myoung-don Oh; Kang Won Choe
Journal:  AIDS       Date:  2007-04-23       Impact factor: 4.177

View more
  12 in total

Review 1.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

2.  The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children.

Authors:  Judy Orikiiriza; Sabrina Bakeera-Kitaka; Victor Musiime; Edison A Mworozi; Peter Mugyenyi; David R Boulware
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

Review 3.  Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review.

Authors:  Ruth Link-Gelles; Harry Moultrie; Shobna Sawry; David Murdoch; Annelies Van Rie
Journal:  Pediatr Infect Dis J       Date:  2014-05       Impact factor: 2.129

Review 4.  Management of individuals requiring antiretroviral therapy and TB treatment.

Authors:  Karen Cohen; Graeme Meintjes
Journal:  Curr Opin HIV AIDS       Date:  2010-01       Impact factor: 4.283

5.  Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome.

Authors:  R Tadokera; G Meintjes; K H Skolimowska; K A Wilkinson; K Matthews; R Seldon; N N Chegou; G Maartens; M X Rangaka; K Rebe; G Walzl; R J Wilkinson
Journal:  Eur Respir J       Date:  2010-09-03       Impact factor: 16.671

6.  Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART.

Authors:  William Worodria; Marguerite Massinga-Loembe; Harriet Mayanja-Kizza; Jane Namaganda; Andrew Kambugu; Yukari C Manabe; Luc Kestens; Robert Colebunders
Journal:  Clin Dev Immunol       Date:  2010-12-08

Review 7.  Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

Authors:  N Kumarasamy; Atul Patel; Sanjay Pujari
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

8.  The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.

Authors:  Naomi F Walker; Cari Stek; Sean Wasserman; Robert J Wilkinson; Graeme Meintjes
Journal:  Curr Opin HIV AIDS       Date:  2018-11       Impact factor: 4.283

9.  Determinant factors associated with occurrence of tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study.

Authors:  Kelemu Tilahun Kibret; Alemayehu Worku Yalew; Belaineh Girma Belaineh; Muluken Melese Asres
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.

Authors:  Lewis John Haddow; Mahomed-Yunus Suleman Moosa; Anisa Mosam; Pravi Moodley; Raveen Parboosing; Philippa Jane Easterbrook
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.